Jerome Schartman

ADVERSE EVENTS AFTER INTRAVITREAL INFLIXIMAB (REMICADE)

MONICA GIGANTI, Paul M. Beer, Nicole Lemanski et al. · Retina · 2010 · 131 citations

Medicine, Ophthalmology, Pharmacotherapy +17

B7 Requirements for Primary and Secondary Protein- and Polysaccharide-Specific Ig Isotype Responses to <i>Streptococcus pneumoniae</i>

Zheng-Qi Wu, Abdul Qayyum Khan, Yi Shen et al. · The Journal of Immunology · 2000 · 64 citations

Life Sciences, Immunology, Microbiology +15

Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema

Lee M. Jampol, Adam R. Glassman, Danni Liu et al. · Ophthalmology · 2018 · 44 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +12

Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy

Maureen G. Maguire, Danni Liu, Susan B. Bressler et al. · JAMA Ophthalmology · 2021 · 33 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +14

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration

Joseph Coney, Ryan Zubricky, Samriddhi Buxy Sinha et al. · International Journal of Retina and Vitreous · 2023 · 16 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +16